New Delhi, June 30, 2020: The Drug Controller General of India (DCGI) has given approval for human clinical trials of COVAXIN, the first potential COVID-19 Vaccine devel-oped in India.
The potential vaccine has been developed by Hyderabad-based Bharat Biotech, in association with Indian Council for Medical Research (ICMR).
Human Trials for Phase I and Phase II are scheduled to start across the country from next month.
COVAXIN is an inactivat-ed vaccine, created from a strain of the infectious SARS-CoV-2 virus.
It has shown promising results in the pre-clinical studies demonstrating exten-sive safety and effective immune responses.
Drug manufacturers and research consortiums global-ly are working at developing a vaccine against the novel corona virus.